• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives

Introduction to 3'-(1,3-Dioxolan-2-yl)biphenyl-3-carboxylic acid (CAS No. 400750-26-7) in Modern Chemical and Pharmaceutical Research

3'-(1,3-Dioxolan-2-yl)biphenyl-3-carboxylic acid, identified by the CAS number 400750-26-7, is a specialized organic compound that has garnered significant attention in the field of chemical and pharmaceutical research due to its unique structural properties and potential applications. This compound belongs to the biphenyl family, characterized by a phenyl ring system linked by a carbon-carbon bond, and incorporates a 1,3-dioxolan moiety, which introduces a cyclic ether structure. Such structural features make it a versatile scaffold for the development of novel molecules with distinct biochemical interactions.

The 1,3-dioxolan group is particularly noteworthy as it serves as a bioisostere for other oxygen-containing heterocycles such as furan or tetrahydrofuran, but with distinct electronic and steric properties. This feature allows for fine-tuning of molecular interactions with biological targets, making 3'-(1,3-Dioxolan-2-yl)biphenyl-3-carboxylic acid a promising candidate for drug discovery efforts. The biphenyl core, on the other hand, is well-known for its role in medicinal chemistry due to its stability and ability to engage in π-stacking interactions, which are crucial for binding affinity in protein-ligand interactions.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors targeting various therapeutic areas, including cancer, inflammation, and neurodegenerative diseases. The structural motif of 3'-(1,3-Dioxolan-2-yl)biphenyl-3-carboxylic acid aligns well with this trend, as it combines the favorable pharmacokinetic properties of biphenyl derivatives with the unique reactivity of the 1,3-dioxolan ring. This has led to its exploration as a key intermediate in synthesizing novel therapeutic agents.

One of the most compelling aspects of this compound is its potential to serve as a building block for designing molecules that interact with biological macromolecules in innovative ways. For instance, studies have demonstrated that biphenyl derivatives can modulate enzyme activity by binding to specific pockets within the active sites of target enzymes. The incorporation of the 1,3-dioxolan group further enhances this capability by introducing additional conformational flexibility and electronic properties that can be exploited to optimize binding affinity and selectivity.

Recent advancements in computational chemistry have enabled researchers to predict the binding modes of such compounds with high accuracy. Molecular docking simulations have shown that 3'-(1,3-Dioxolan-2-yl)biphenyl-3-carboxylic acid can effectively interact with various protein targets, including kinases and transcription factors implicated in diseases like cancer. These simulations have guided experimental efforts by highlighting key residues involved in binding and suggesting modifications that could enhance potency.

The synthesis of 3'-(1,3-Dioxolan-2-yl)biphenyl-3-carboxylic acid presents an interesting challenge due to the need to introduce both the biphenyl and 1,3-dioxolan moieties in a regioselective manner. Traditional synthetic routes often involve multi-step processes that require careful optimization to ensure high yields and purity. However, recent innovations in synthetic methodologies have streamlined these processes, making it more feasible to produce this compound on a larger scale for research purposes.

In addition to its pharmaceutical applications, 3'-(1,3-Dioxolan-2-yl)biphenyl-3-carboxylic acid has shown promise in materials science. Its ability to form stable π-stacking interactions makes it a candidate for developing organic semiconductors or liquid crystals. These materials are essential components in advanced electronic devices such as organic light-emitting diodes (OLEDs) and solar cells. The unique structural features of this compound could contribute to the design of more efficient and sustainable materials.

The exploration of 3'-(1,3-Dioxolan-2-yl)biphenyl-3-carboxylic acid also extends into environmental chemistry. Researchers are investigating its potential as a ligand in catalytic systems designed for green chemistry applications. By serving as a chelating agent for metal ions, this compound could facilitate catalytic reactions under mild conditions, reducing energy consumption and minimizing waste generation—a critical focus in sustainable chemical manufacturing.

As our understanding of biological systems continues to evolve, so does the demand for innovative molecular tools like 3'-(1,3-Dioxolan-2-yl)biphenyl-3-carboxylic acid. Ongoing research aims to uncover new applications for this compound by exploring its interactions with diverse biological targets. Collaborative efforts between chemists and biologists are essential in translating these findings into tangible therapeutic benefits.

The future prospects for CAS No. 400750-26-7 are bright, with continued interest expected from both academic institutions and pharmaceutical companies. As computational methods improve and synthetic techniques become more efficient, the accessibility of this compound will likely increase, fostering further innovation across multiple scientific disciplines.

• 35848-99-8(Benzoic acid, 4-(diethoxymethyl)-, ethyl ester)
• 40681-88-7(4-(1,3-dioxolan-2-yl)benzaldehyde)
• 81172-89-6(Terephthaldehyde monodiethylacetal)
• 120465-56-7(Benzoic acid, 4-(dimethoxymethyl)-)
• 495390-90-4(Ethanol, 2-[2-[2-(1,3-dioxolan-2-ylmethoxy)ethoxy]ethoxy]-, benzoate)
• 400750-15-4(2'-(1,3-Dioxolan-2-yl)biphenyl-3-carboxylic acid)
• 150990-60-6(3-(Diethoxymethyl)benzaldehyde)
• 68348-23-2(3-(1,3-dioxolan-2-yl)benzaldehyde)
• 124038-36-4(Benzoic acid, 3-(1,3-dioxolan-2-yl)-, methyl ester)
• 400744-10-7(4'-(1,3-Dioxolan-2-yl)biphenyl-3-carboxylic acid)